Stay updated on Lenvatinib Pembrolizumab in Hepatobiliary Tumors Clinical Trial

Sign up to get notified when there's something new on the Lenvatinib Pembrolizumab in Hepatobiliary Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Lenvatinib Pembrolizumab in Hepatobiliary Tumors Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    The page has removed a citation regarding the genetic basis for clinical response to CTLA-4 blockade in melanoma, which included an erratum reference.
    Difference
    0.2%
    Check dated 2025-05-08T14:20:03.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.0%
    Check dated 2025-05-01T06:33:10.000Z thumbnail image
  4. Check
    27 days ago
    No Change Detected
  5. Check
    34 days ago
    Change Detected
    Summary
    The web page has undergone significant changes, including the removal of detailed descriptions of a clinical study involving lenvatinib and pembrolizumab for advanced hepatobiliary tumors, while adding a new study on combinational immunotherapy for cholangiocarcinoma. The revision number has also been updated.
    Difference
    35%
    Check dated 2025-04-16T20:52:29.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.0%
    Check dated 2025-04-09T15:59:06.000Z thumbnail image
  7. Check
    49 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.2%
    Check dated 2025-04-02T00:22:46.000Z thumbnail image
  8. Check
    85 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    0.7%
    Check dated 2025-02-24T23:04:59.000Z thumbnail image

Stay in the know with updates to Lenvatinib Pembrolizumab in Hepatobiliary Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Lenvatinib Pembrolizumab in Hepatobiliary Tumors Clinical Trial page.